Strategies in Overcoming Homologous Recombination Proficiency and PARP Inhibitor Resistance.

ABSTRACT: Ovarian cancer is the second most common gynecologic malignancy in the United States and the most common cause of gynecologic cancer-related death. The majority of ovarian cancers ultimately recur despite excellent response rates to upfront platinum- and taxane-based chemotherapy. Maintenance therapy after frontline treatment has emerged in recent years as an effective tool for extending the platinum-free interval of these patients. Maintenance therapy with PARP inhibitors (PARPis), in particular, has become part of standard of care in the upfront setting and in patients with platinum-sensitive disease. Homologous recombination deficient (HRD) tumors have a nonfunctioning homologous recombination repair (HRR) pathway and respond well to PARPis, which takes advantage of synthetic lethality

SUBMITTER: Goel N 

PROVIDER: S-EPMC9066363 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature